
|Articles|January 15, 2005
FDA approval of AMD treatment considered 'a milestone'
On Dec. 17, Eyetech Pharmaceuticals (EYET) announced FDA approval of pegaptanib sodium injection (Macugen) for the treatment of neovascular ("wet") age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmic innovation by the decades: The 2000s
2
The Residency Report: Social media and the modern ophthalmologist
3
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
4
FDA approves Rayner’s RayOne EMV Toric intraocular lens
5